LEO Pharma Ireland – FDA 483, Jun 24, 2022
An FDA inspection of LEO Pharma Ireland in Dublin identified two significant observations. The firm failed to maintain adequate air pressure and dust control equipment, and its electronic records were found to be unreliable due to inconsistencies between logbook entries and the Business Management System. Additionally, the inspection revealed defects in the plumbing system, including an undetected leak, and a lack of procedures for frequent physical inspections, which could lead to drug product contamination.
ID · e9f0b464-606c-46fc-9f09-0a47ce18d194
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.